Volume 28, Number 10—October 2022
Sindbis Virus Antibody Seroprevalence in Central Plateau Populations, South Africa
We report a higher percentage of Sindbis virus-specific IgG in serum from patients attending a rheumatology clinic (18.8%) compared with healthy residents (9.6%) and patients with acute febrile illness (9.4%) in Free State Province, South Africa. Sindbis virus infection should be considered a potential cause of arthritis in South Africa.
Sindbis virus (SINV) is a mosquitoborne virus that belongs to the Togaviridae family; SINV is considered an arthritogenic alphavirus, which is known to cause self-limiting acute febrile illness (AFI) in Africa, Australia, Asia, and Europe and occasional debilitating arthritis that can persist for years after infection (1). Outbreaks are associated with heavy rainfall and temperature changes that favor mosquito breeding. Associations between SINV infection and acute or chronic arthralgia and myalgia have been described in Finland and Sweden (2,3). The extent of chronic debilitating disease caused by SINV in South Africa remains largely unknown.
SINV was identified as a cause of human disease in South Africa in 1963, and subsequent studies confirmed that the virus was present in mosquito populations in the central plateau region, which includes Free State Province (4). We investigated the seroprevalence of SINV in selected human populations of Free State Province. We used an in-house ELISA to detect SINV-specific IgG in serum and confirmed positive serum samples using neutralization assays (Appendix). We screened a total of 568 stored serum samples retrospectively and anonymously. All available stored samples were tested and included 165 serum specimens submitted to the Division of Virology, National Health Laboratory Service, for routine clinical pathology tests from patients who attended the rheumatology clinic at the Universitas Hospital, Bloemfontein, South Africa, during 2013–2017 and 267 serum samples submitted to the National Health Laboratory Service during 2008–2010 from patients with AFI and no confirmed diagnosis. No clinical data were available; however, most attendees at the rheumatology clinic had chronic arthritis. We also included 136 serum samples from healthy volunteers that were collected during 2016–2017 for seroepidemiology studies of Crimean-Congo hemorrhagic fever virus and other vectorborne diseases.
We confirmed 11 serum samples were negative for SINV antibodies using a commercial immunofluorescence assay (EuroImmun, https://www.euroimmun.com); these samples were used to determine ELISA cutoff values. Positive control serum was obtained from 1 patient who had a laboratory-confirmed SINV infection. We obtained institutional ethics approval for this study from the Health Sciences Research Ethics Committee, University of the Free State (HSREC approval no. 95/2016C), and informed consent was available for samples collected for the seroepidemiology study (HSREC approval no. 34/2016), negative control serum panel (approval no. ETOVS 152/06), and positive control (approval no. ETOVS 118/06).
We determined optimal reagent dilutions for the ELISA using checkerboard titrations. We diluted serum samples 1:100 and tested for reactions to SINV-specific and mock antigens (Appendix). We detected reactions using horse radish peroxidase-conjugated antihuman IgG (1:8000) and 2,2′-azino-di-3-ethylbenzthiazoline-6-sulfonate (SeraCare Life Sciences, https://www.seracare.com). We measured optical density (OD) values at 405 nm and calculated net OD values by subtracting each sample OD obtained with mock antigen from the OD value obtained with SINV antigen. To normalize data, percent positivity (PP) for each sample was calculated as PP = (mean net sample OD ÷ mean net OD of the positive control) × 100.
We used the mean PP value +2 SD for 11 SINV-negative serum samples derived from a total of 83 replicates to determine the cutoff value between positive and negative samples (Appendix). We tested SINV antibody-positive serum samples for neutralizing antibodies using a 50% tissue culture infectious dose serum neutralization assay; samples were considered positive for neutralizing antibodies if the titer was >log10 1.0, equal to a serum dilution >1:10 (5).
We detected SINV antibodies in 31/165 (18.8%) serum samples from patients who attended the rheumatology clinic, 13/136 (9.6%) samples from residents of SINV-endemic regions (high risk), and 25/267 (9.4%) samples from patients with AFI but no diagnosis (Table). Of the total number of SINV-positive samples, ≈45% of the samples were from patients who attended the rheumatology clinic (Table). We detected neutralizing antibodies with endpoint titers ranging from 1:20 to >1:640 in 65 of 69 SINV antibody-positive serum samples; 4 samples showed discordant results.
SINV seroprevalence in South Africa for 2006–2009 was 5.4% and increased to 12% after heavy rainfalls in 2010 (6). A 9.4%–9.6% seroprevalence in persons at high risk and for febrile patients is within an expected range, considering that the samples were collected over a 10-year period during which substantial rainfall in Free State Province was associated with arbovirus outbreaks (7,8). Rheumatology clinic attendees had the highest percentage (18.8%) of samples with SINV-specific IgG, compared with 9.4% for residents from SINV-endemic regions and 9.6% for patients with AFI. However, limitations exist when comparing cohorts collected at different time points, and undetected outbreaks might have been responsible for higher seroprevalence among the rheumatology clinic patients. Prospective studies in national tertiary or specialist healthcare clinics should elucidate the contribution of viral infections to chronic arthritis. Our results suggest that associations between SINV infections and arthritis have been underreported in South Africa, and SINV infection should be considered a potential cause of arthritis in this country.
Ms. Kennedy is a postgraduate student in the Division of Virology, University of the Free State, Bloemfontein, South Africa. Her research interests focus on arboviruses and the public health implications of arboviral infections.
This study was supported by funds from the South African Research Chair in Vectorborne and Zoonotic Diseases (grant no. 98346), which was hosted by the University of the Free State, funded by the Department of Science and Technology, and administered by the National Research Foundation.
- Adams MJ, Lefkowitz EJ, King AMQ, Harrach B, Harrison RL, Knowles NJ, et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol. 2017;162:2505–38. DOIPubMedGoogle Scholar
- Kurkela S, Helve T, Vaheri A, Vapalahti O. Arthritis and arthralgia three years after Sindbis virus infection: clinical follow-up of a cohort of 49 patients. Scand J Infect Dis. 2008;40:167–73. DOIPubMedGoogle Scholar
- Gylfe Å, Ribers Å, Forsman O, Bucht G, Alenius GM, Wållberg-Jonsson S, et al. Mosquitoborne Sindbis virus infection and long-term illness. Emerg Infect Dis. 2018;24:1141–2. DOIPubMedGoogle Scholar
- Jupp PG, Blackburn NK, Thompson DL, Meenehan GM. Sindbis and West Nile virus infections in the Witwatersrand-Pretoria region. S Afr Med J. 1986;70:218–20.PubMedGoogle Scholar
- Pearce MC, Venter M, Schouwstra T, Van Eeden C, Jansen van Vuren P, Paweska J, et al. Serum neutralising antibody response of seronegative horses against lineage 1 and lineage 2 West Nile virus following vaccination with an inactivated lineage 1 West Nile virus vaccine. J S Afr Vet Assoc. 2013;84:1–4. DOIGoogle Scholar
- Storm N, Weyer J, Markotter W, Kemp A, Leman PA, Dermaux-Msimang V, et al. Human cases of Sindbis fever in South Africa, 2006-2010. Epidemiol Infect. 2014;142:234–8. DOIPubMedGoogle Scholar
- Archer BN, Thomas J, Weyer J, Cengimbo A, Landoh DE, Jacobs C, et al. Epidemiologic investigations into outbreaks of Rift Valley fever in humans, South Africa, 2008–2011. Emerg Infect Dis. 2013;19:1918–25. DOIPubMedGoogle Scholar
- Weyer J, Thomas J, Leman PA, Grobbelaar AA, Kemp A, Paweska JT. Human cases of Wesselsbron disease, South Africa 2010-2011. Vector Borne Zoonotic Dis. 2013;13:330–6. DOIPubMedGoogle Scholar
TableCite This Article
Original Publication Date: September 15, 2022
Table of Contents – Volume 28, Number 10—October 2022
|EID Search Options|
|Advanced Article Search – Search articles by author and/or keyword.|
|Articles by Country Search – Search articles by the topic country.|
|Article Type Search – Search articles by article type and issue.|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Felicity Burt, Division of Virology, Faculty of Health Sciences, National Health Laboratory Service and University of the Free State, Bloemfontein, 9301, South Africa